Kathleen Devejian, APRN
Primary Care · Hampstead, NHNPI 1528579257
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 34.9% of the total. Reporting peaked in 2024 at $1,661 and has fallen 52.8% since, to $783 in 2025. Among primary care clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$505
- Merck$209
- Lundbeck LLC$149
- Pfizer$133
- GSK$122
- plus $760 from 13 others
What the payments were for
- Food & beverage$2,887100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $1,009 |
| AstraZeneca | 24 | $505 |
| Merck | 8 | $209 |
| Lundbeck LLC | 7 | $149 |
| Pfizer | 7 | $133 |
| GSK | 6 | $122 |
| Lilly USA, LLC | 6 | $107 |
| Exact Sciences | 4 | $104 |
| Novo Nordisk | 5 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $93 |
| Paratek Pharmaceuticals, Inc. | 3 | $64 |
| Axsome Therapeutics, Inc. | 3 | $60 |
| Boehringer Ingelheim | 3 | $52 |
| Baxter Healthcare | 1 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Amgen | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
How this compares
$2,887 in reported general payments places this provider in the 90th percentile of 31 primary care providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $47,460 |
| JardianceEmpagliflozin | 18 | $30,400 |
| MounjaroTirzepatide | 16 | $28,143 |
| EliquisApixaban | 21 | $24,779 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $8,238 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,217 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $5,712 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $2,285 |
| Rosuvastatin Calcium | 128 | $1,692 |
| Gabapentin | 69 | $1,542 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,485 |
| Atorvastatin Calcium | 184 | $1,329 |
| Omeprazole | 61 | $1,023 |
| Buspirone Hcl | 33 | $967 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $93 | $47,46039 claims |
| Boehringer IngelheimJardiance | $52 | $30,40018 claims |
| Lilly USA, LLCMounjaro | $107 | $28,14316 claims |
| PfizerEliquis | $133 | $24,77921 claims |
| AstraZenecaSymbicort | $505 | $8,23822 claims |
| GSKBreo Ellipta | $122 | $7,21718 claims |
| AbbVieSynthroid | $1,009 | $85318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 31 primary care providers in New Hampshire.
Other primary care in Hampstead
- Jean SchwartzLebanon$9K
- Beena RajagopalNashua$6K
- Kamila ZlotoschDurham$2K
- Deborah JensenHopkinton$801
- Tina McGuirkNashua$760
- Jennifer TichichLaconia$709
- Melissa-Jo NasonConway$704
- Stephane CampagnaLittleton$680
- Emily GrattanSomersworth$647
- Lynn ConsolmagnoPortsmouth$601
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.